osu-03012 and Cryptococcosis

Only one new class of antifungal drugs has been introduced into clinical practice in the last 30 years, and thus the identification of small molecules with novel mechanisms of action is an important goal of current anti-infective research. Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity of AR-12, a celecoxib derivative which has been tested in a phase I clinical trial as an anticancer agent. AR-12 inhibits fungal acetyl coenzyme A (acetyl-CoA) synthetase in vitro and is fungicidal at concentrations similar to those achieved in human plasma. AR-12 has a broad spectrum of activity, including activity against yeasts (e.g., Candida albicans, non-albicans Candida spp., Cryptococcus neoformans), molds (e.g., Fusarium, Mucor), and dimorphic fungi (Blastomyces, Histoplasma, and Coccidioides) with MICs of 2 to 4 μg/ml. AR-12 is also active against azole- and echinocandin-resistant Candida isolates, and subinhibitory AR-12 concentrations increase the susceptibility of fluconazole- and echinocandin-resistant Candida isolates. Finally, AR-12 also increases the activity of fluconazole in a murine model of cryptococcosis. Taken together, these data indicate that AR-12 represents a promising class of small molecules with broad-spectrum antifungal activity.

Topics: Animals; Antifungal Agents; Candida; Caspofungin; Celecoxib; Cryptococcosis; Cryptococcus neoformans; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Fungal; Drug Synergism; Echinocandins; Fluconazole; Gene Expression Regulation, Fungal; Lipopeptides; Male; Mice, Inbred Strains; Microbial Sensitivity Tests; Pneumocystis; Pyrazoles; Saccharomyces cerevisiae; Sulfonamides